Catalog No.
VXX00201
Species reactivity
Clostridioides difficile (Peptoclostridium difficile)
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Applications
Neutralization, SPR
Target
toxA, TcdA, Toxin A, Clostridioides difficile (Peptoclostridium difficile),Clostridium difficile Toxin
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P16154
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
PA50
Note
For research use only. Not suitable for clinical or therapeutic use.
Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab., PMID:25486992
The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model., PMID:25698490
Masking autoprocessing of Clostridium difficile toxin A by the C-terminus combined repetitive oligo peptides., PMID:25725153
Development of microbeads of chicken yolk antibodies against Clostridium difficile toxin A for colonic-specific delivery., PMID:25799315
Identification of toxemia in patients with Clostridium difficile infection., PMID:25885671
A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model., PMID:25924765
A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters., PMID:26036797
Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis., PMID:26178385
Recombinant lipoprotein-based vaccine candidates against C. difficile infections., PMID:26245825
Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A., PMID:26271033
Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection., PMID:26964649
Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers., PMID:27079932
Production and Characterization of Chemically Inactivated Genetically Engineered Clostridium difficile Toxoids., PMID:27233688
Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model., PMID:27336843
A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection., PMID:27413067
Site-specific phosphorylation and microtubule dynamics control Pyrin inflammasome activation., PMID:27482109
Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection., PMID:27502696
Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin., PMID:27527088
A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile., PMID:27770789
Colon-Targeted Delivery of IgY Against Clostridium difficile Toxin A and B by Encapsulation in Chitosan-Ca Pectinate Microbeads., PMID:27826799
Clostridium difficile Toxin A Undergoes Clathrin-Independent, PACSIN2-Dependent Endocytosis., PMID:27942025
Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains., PMID:28125650
Mucosal Antibodies to the C Terminus of Toxin A Prevent Colonization of Clostridium difficile., PMID:28167669
Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab., PMID:28232034
Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface., PMID:28705932
A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells., PMID:29180448
Adaptive immune response to Clostridium difficile infection: A perspective for prevention and therapy., PMID:29272036
Application of Assisted Design of Antibody and Protein Therapeutics (ADAPT) improves efficacy of a Clostridium difficile toxin A single-domain antibody., PMID:29396522
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?, PMID:29534621
Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting., PMID:29632249
Difference in Mono-O-Glucosylation of Ras Subtype GTPases Between Toxin A and Toxin B From Clostridioides difficile Strain 10463 and Lethal Toxin From Clostridium sordellii Strain 6018., PMID:30622517
Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model., PMID:30736358
Vaccination against Clostridium difficile by Use of an Attenuated Salmonella enterica Serovar Typhimurium Vector (YS1646) Protects Mice from Lethal Challenge., PMID:31138615
Rapid Detection of Clostridium difficile Toxins in Stool by Raman Spectroscopy., PMID:31279995
Proteomic profiling of precipitated Clostridioides difficile toxin A and B antibodies., PMID:31718902
Development of a new serological assay for the diagnosis of Clostridium difficile infections with prognostic value., PMID:31733265
Therapeutic Mechanism of Macrophage Inflammatory Protein 1 α Neutralizing Antibody (CCL3) in Clostridium difficile Infection in Mice., PMID:31793629
Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis., PMID:32053529
Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum., PMID:33164145
Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B., PMID:33370413
Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Enhances Adaptive Immunity to C difficile Toxin B., PMID:33444574
Facile Affinity Maturation of Single-Domain Antibodies Using Next-Generation DNA Sequencing., PMID:35157277
Neutralizing epitopes on Clostridioides difficile toxin A revealed by the structures of two camelid VHH antibodies., PMID:36466927
Corrigendum: Structure-guided design of a potent Clostridioides difficile toxin A inhibitor., PMID:37065148
Establishment of a Novel Detection Platform for Clostridioides difficile Toxin Genes Based on Orthogonal CRISPR., PMID:37378559
A fine-tuned yeast surface-display/secretion platform enables the rapid discovery of neutralizing antibodies against Clostridioides difficile toxins., PMID:37749574
Monoclonal antibody-mediated neutralization of Clostridioides difficile toxin does not diminish induction of the protective innate immune response to infection., PMID:38701911
Development of two recombinant vaccines against Clostridioides difficile infection and immunogenicity in pregnant sows and neonatal piglets., PMID:39127403
Structural insight into recognition of Clostridioides difficile toxin A by novel neutralizing nanobodies targeting QTIN-like motifs within its receptor-binding domain., PMID:39577542
Oral Exposure to Clostridium difficile Toxin A Aggravates Food Allergy by Intestinal Barrier Destruction, Mast Cell Activation, and Th2-Biased Immune Responses., PMID:39847683
For research use only. Not for human or drug use.
